14064-15-4

Usage

InChI:InChI=1/C6H4Cl.3CH3.Sn/c7-6-4-2-1-3-5-6;;;;/h2-5H;3*1H3;/rC9H13ClSn/c1-11(2,3)9-6-4-8(10)5-7-9/h4-7H,1-3H3

Upstream product

• 108-86-1 bromobenzene 
• 1066-45-1 trimethyltin(IV)chloride 
• 873-77-8 (4-chlorphenyl)magnesium bromide 
• 1066-44-0 trimethyltin bromide 
• 637-87-6 1-Chloro-4-iodobenzene 
• 661-69-8 hexamethyldistannane 
• 106-47-8 4-chloro-aniline 
• 56075-36-6 1-(4-chlorophenyl)-2-(methylsulfonyl)diazene 
• 51833-36-4 4-chlorophenylmagnesium chloride 

Downstream Products

• 1745-18-2 1-allyl-4-chlorobenzene 
• 2050-68-2 4,4'-dichlorobiphenyl 
• 1118-14-5 trimethyltin acetate 
• 135741-06-9 methyl 3-<(benzyloxycarbonyl)amino>-2-(methoxycarbonyl)-5-oxo-5-(p-chlorophenyl)pentanoate 
• 135773-14-7 methyl 2-(methoxycarbonyl)-5-oxo-5-(p-chlorophenyl)-3-N-<(+/-)-syn-4,5-diphenyl-2-oxazolidinonyl>pentanoate 
• 6333-79-5 4-chloro-N-methylbenzenesulfonamide 
• 7497-60-1 (4-Chlorophenyl)(4-nitrophenyl)methanone 
• 90-98-2 4,4'-Dichlorobenzophenone 
• 133965-80-7 4'-chloro-2,4-dinitroazobenzene 
• 352-33-0 1-Chloro-4-fluorobenzene 
• 6242-97-3 4-(4-nitrophenyl)chlorobenzene 
• 81292-95-7 4-Chlor-1-benzolsulfonsaeure-trimethylsilylester 
• 676-89-1 trimethyltin tetrafluoroborate 
• 57110-59-5 Pt(cyclo-octa-1,5-diene)(C₆H₄Cl-p)Cl 

Relevant academic research and scientific papers

Visible-Light-Driven Synthesis of Arylstannanes from Arylazo Sulfones

The visible-light-driven preparation of (hetero)aryl stannanes was carried out under both photocatalyst- and metal-free conditions via irradiation of arylazo sulfones in the presence of hexaalkyldistannanes. The reaction shows a high efficiency and a wide substrates scope. The resulting crude organotin derivatives can be directly employed in a Stille protocol.

Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors

(Figure Presented). As a result of our efforts to discover novel p53:MDM2 protein-protein interaction inhibitors useful for treating cancer, the potent and selective MDM2 inhibitor NVP-CGM097 (1) with an excellent in vivo profile was selected as a clinical candidate and is currently in phase 1 clinical development. This article provides an overview of the discovery of this new clinical p53:MDM2 inhibitor. The following aspects are addressed: mechanism of action, scientific rationale, binding mode, medicinal chemistry, pharmacokinetic and pharmacodynamic properties, and in vivo pharmacology/toxicology in preclinical species.

CRYSTALLINE FORM OF AN INHIBITOR OF MDM2/4 AND P53 INTERACTION

A crystalline form of (S)-1-(4-Chloro-phenyl)-7-isopropoxy-6-methoxy-2-(4-{methyl-[4-(4-methyl-3-oxo-piperazin-1-yl)-trans-cyclohexylmethyl]-amino}-phenyl)-1,4-dihydro-2H-isoquinolin-3-one, which is useful in the treatment of a disease or disorder associated with the interaction between p53, or variants thereof, and MDM2 and/or MDM4, or variants thereof, respectively.

Synthesis of aryl trimethylstannanes from aryl amines: A sandmeyer-type stannylation reaction

Sandmeyer-type stannylation: Stille coupling is one of the most powerful coupling reactions for C-C bond formation, whereas there are only limited methods to access aryl stannane compounds. A mild stannylation process based on a Sandmeyer-type transformation using aromatic amines as the starting materials is described. DCE: 1,2-dichloroethane. Copyright

Crystalline form of an inhibitor of MDM2/4 and p53 interaction

A crystalline form of (S)-1-(4-Chloro-phenyl)-7-isopropoxy-6-methoxy-2-(4-{methyl-[4-(4-methyl-3-oxo-piperazin-1-yl)-trans-cyclohexylmethyl]-amino}-phenyl)-1,4-dihydro-2H-isoquinolin-3-one, which is useful in the treatment of a disease or disorder associated with the interaction between p53, or variants thereof, and MDM2 and/or MDM4, or variants thereof, respectively,

HYDROXY SUBSTITUTED ISOQUINOLINONE DERIVATIVES

The invention relates to compounds of formula (I): as defined in the application. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of MDM2 and/or MDM4, or variants thereof.

Azoxy compound

An azoxy compound represented by the following general formula STR1 wherein R1 denotes a hydrogen atom, a halogen atom, a hydroxyl group, a lower alkoxy group, a lower alkoxy-lower alkoxy group or a group of the formula X1 --C C--CH

SYNTHESIS OF ORGANOTRIALKYLSTANNANES. THE REACTION BETWEEN ORGANIC HALIDES AND HEXAALKYLDISTANNANES IN THE PRESENCE OF PALLADIUM COMPLEXES

The aryl halides YC6H4X (X=Br or I) have been shown to react with the distannanes (R3Sn)2 (R=n-Bu or Me) in toluene in the presence of or to give the compounds YC6H4SnR3 for (a) R=n-Bu, Y=H, p-OMe, o-Me, p-Me, m-Cl, p-Cl, m-CN, p-COCH3 and m-NO2, and (b) R=Me, Y=H, p-OMe, p-Me, p-CN, p-COCH3, m-NO2 and p-NO2.Benzyl halides YC6H4CH2X (X=Cl or Br) similarly give YC6H4CH2SnR3 for (a) R=n-Bu, Y=H, m-OMe, p-OMe, m-Cl, m-CN, and m-NO2, and (b) R=Me, Y=m-Cl, m-CN, p-CN and m-NO2.These reactions are of special value as preparative procedures in cases in which Grignard or organolithium reagents cannot be used.Allyl chloride and bromide were likewise shown to react with (n-Bu3Sn)2 to give CH2=CHCH2SnBu3, but n-BuCl and n-BuBr gave only a trace of n-Bu4Sn.The mixed dimetallo species n-Bu3SnSiMe3 was shown to react with aryl bromides YC6H4Br (X=H, p-OMe, p-Me, or p-Cl) to give the arylsilicon compounds YC6H4SiMe3, with no aryltin products.